Endoscopic ultrasound-guided neurolysis in advanced pancreatic cancer : current status

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ..

Pancreatic cancer has a very poor prognosis with patients often presenting with locally advanced, inoperable or metastatic disease. A significant proportion of patients have visceral pain due to perineural infiltration or coeliac plexus involvement by the tumour. This pain is difficult to control and may become refractory to conventional pain management. Therefore, coeliac plexus neurolysis (CPN) has been proposed to ablate the neuronal transmission pathway of pain permanently. CPN is recommended for those who have uncontrolled pain, are experiencing unacceptable opioid adverse effects or are receiving escalating doses of analgesics. It is not known whether CPN performed at diagnosis as the first-line treatment ('early') would impact short-term and long-term pain control and quality of life. NICE has recommended (2018) a randomised trial comparing early endoscopic ultrasound-guided coeliac plexus neurolysis (EUS-CPN) with on-demand EUS-CPN in pancreatic cancer. In this context, we will review the current evidence on its clinical benefits.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:12

Enthalten in:

BMJ supportive & palliative care - 12(2022), 1 vom: 11. März, Seite 22-28

Sprache:

Englisch

Beteiligte Personen:

Hickman, Katy [VerfasserIn]
Godfrey, Edmund [VerfasserIn]
Ajithkumar, Thankamma [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
Pain
Pancreatic
Quality of life
Review
Symptoms and symptom management

Anmerkungen:

Date Completed 21.02.2022

Date Revised 21.02.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1136/bmjspcare-2021-002905

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM331764385